<DOC>
	<DOCNO>NCT02975102</DOCNO>
	<brief_summary>The primary objective investigation show performance CBL-101 Eye Drops non-inferior Vismed® Multi eye drop subject moderate severe keratoconjunctivitis sicca 28 day , assess safety CBL-101 Eye Drops 90-day period treatment administer 3 6 time per day .</brief_summary>
	<brief_title>A Study Evaluate Performance Safety CBL-101 Versus Vismed® Multi Eye Drops Management Dry Eye</brief_title>
	<detailed_description>Study duration approximately 15 week screen last visit . Subjects visit clinic approximately 5 time .</detailed_description>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Subjects must legal age ( least 18 ) date Informed Consent Form ( ICF ) sign capacity provide voluntary informed consent 2 . Subjects must able read , understand , provide write informed consent Ethics Committee ( EC ) approve ICF 3 . Subjects able willing comply treatment followup , study procedure 4 . Subjects use tear substitute least 3 month prior inclusion , use multidose preservativefree ART ( Aqualarm U.P . povidone 2 % eye drop 10 mL bottle ) 6 time day least 2 week immediately prior randomization 5 . Subjects score ≥ 1 least 2 7 follow symptom ( rat 0 4 ) : sensation dryness , foreign body , burning , sting , itch , blur vision , sensitivity light 6 . Subjects least 1 eye follow sign keratoconjunctivitis sicca : Schirmer test without anesthesia ≤ 9 mm per 5 min inclusion visit ( Visit 2 ) Tear breakup time ≤ 10sec ( mean 3 measurement ) screen visit inclusion visit Total ocular surface stain score ≥ 4 ≤ 9 screen visit inclusion visit . This assessment combine corneal , nasal temporal bulbar conjunctival fluorescein staining , grade 05 accord Oxford Scheme 7 . Subjects decimal visual acuity ( VA ) habitual correction equal well 0.1 ( Monoyer chart ) eye 8 . Subjects systemic treatment receive stable systemic treatment ( unchanged 1 month longer ) 9 . Female subject childbearing potential negative urine pregnancy test result screen Ocular Exclusion Criteria 1 . Subjects moderate severe blepharitis define least moderate ( score ≥ 2 range 0 3 ) eyelid margin hyperemia moderate eyelid swell least moderate eyelid debris moderate plugging meibomian glands 2 . Subjects severe ocular dryness accompany one following : Lid abnormality ( except mild blepharitis ) Corneal disease Ocular surface metaplasia Filamentary keratitis Corneal neovascularization 3 . Subjects currently wear contact lens wear contact lens within 90 day prior study start 4 . Subjects receive ocular surgery , include laser surgery , either eye within 180 day prior study start 5 . Subjects history ocular trauma , nondry eye ocular inflammation , ocular infection within 90 day prior study start 6 . Subjects history ocular allergic disease ocular herpes within 1 year prior study start 7 . Subjects history inflammatory ulcerative keratitis , recurrent corneal erosion , uveitis Treatment Exclusion Criteria 8 . Subjects know hypersensitivity contraindication ingredient test comparator product ART 9 . Subjects initiation , change , concomitant medication could affect dry eye within 30 day prior Visit 1 ( Screening ) plan initiation change medication study 10 . Subjects receive ocular therapy ( either eye ) ophthalmic medication , except tear substitute , within 2 week prior study start 11 . Subjects expect receive ocular therapy study 12 . Subjects treat topical ocular steroidal nonsteroidal antiinflammatory medication within 30 day prior study start 13 . Subjects expect receive ocular therapy immunosuppressant ( e.g . cyclosporine ) study use ocular immunosuppressant within 90 day prior study start 14 . Subjects receive occlusion therapy lacrimal punctum plug within 90 day prior study start General Exclusion Criteria 15 . Female subject sexually active fall 1 follow category : Postmenopausal Surgically sterile Using one follow birth control method throughout duration study : Intrauterine device ( least 14 day prior study start ) Barrier method ( condom diaphragm ) spermicide ( least 14 day prior study start ) Hormonal contraception ( dose formulation least 6 month ) 16 . Females breastfeed 17 . Subjects participate drug device clinical investigation within 30 day prior entry study , period study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>